Synopsis
Synopsis
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Capval
2. Capval Tropfen
3. Embonate, Noscapine Hydrogen
4. Hydrochloride, Noscapine
5. Hydrogen Embonate, Noscapine
6. Librochin Prikkelhoest
7. Narcotine
8. Noscapect
9. Noscapine Hydrochloride
10. Noscapine Hydrogen Embonate
11. Prikkelhoest, Librochin
12. Tropfen, Capval
13. Tuscalman
1. 128-62-1
2. Narcotine
3. Tusscapine
4. Methoxyhydrastine
5. Terbenol
6. Capval
7. Coscopin
8. Narcompren
9. Narcosine
10. Noscapin
11. Vadebex
12. (-)-narcotine
13. Narcotin
14. Narkotin
15. Noscapalin
16. Opianine
17. Opianin
18. Narcotussin
19. Longatin
20. Nectadon
21. Nicolane
22. Nipaxon
23. Lyobex
24. Opian
25. Alpha-narcotine
26. O-methylnarcotoline
27. Coscotabs
28. Noscapinum
29. Key-tusscapine
30. Longactin
31. Noscapal
32. Noscapina
33. Hederix (free Base)
34. (-)-alpha-narcotine
35. L-alpha-narcotine
36. Gnoscopine
37. Narcotinum
38. Noscopine
39. (-)-.alpha.-narcotine
40. Nsc 5366
41. Nsc-5366
42. .alpha.-narcotine
43. Dl-narcotine
44. (+/-)-noscapine
45. L-.alpha.-narcotine
46. A4c6we7bzn
47. 8v32u4aoqu
48. Alpha-gnoscopine
49. (3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-2-benzofuran-1(3h)-one
50. (s)-6,7-dimethoxy-3-((r)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)isobenzofuran-1(3h)-one
51. Chebi:73237
52. Nsc5366
53. (3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3h-2-benzofuran-1-one
54. Dsstox_cid_3385
55. Dsstox_rid_77007
56. Dsstox_gsid_23385
57. 1(3h)-isobenzofuranone, 6,7-dimethoxy-3-((5r)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (3s)-rel-
58. 1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)-isoquinolin-5-yl), (s-(r*,s*))-
59. 1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (r*,s*)-
60. 6035-40-1
61. Narcotine Alkaloid
62. Noskapin
63. .alpha.-gnoscopine
64. Noscapine Dl-form
65. L-alpha-noscapine
66. 8-methoxyhydrastin
67. Coscopin (van)
68. (3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-2h,5h,6h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-1,3-dihydro-2-benzofuran-1-one
69. Smr000059119
70. (+-)-noscapine
71. (-)-.alpha.-norcotine
72. (-)-alpha-norcotine
73. (+-)-alpha-narcotine
74. 1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (s-(r*,s*))-
75. 1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-, [s-(r*,s*)]-
76. Noscapinum [inn-latin]
77. Noscapina [inn-spanish]
78. Unii-a4c6we7bzn
79. Unii-8v32u4aoqu
80. Ccris 9304
81. Nsc-96350
82. Hsdb 3372
83. Noscapine [usp:inn:ban:jan]
84. .beta.-narcotine
85. Noscapine (tn)
86. (-)-noscapine
87. Ncgc00016388-01
88. [s-(r*,s*)]-6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-1(3h)-isobenzofuranone
89. Cas-128-62-1
90. Prestwick_959
91. (-)-a-narcotine
92. Einecs 204-899-2
93. Nsc 96350
94. 1-.alpha.-narcotine
95. Brn 0099933
96. Tocris-1697
97. Narcotine, (+-)-
98. Noscapine [inn]
99. Noscapine [jan]
100. Noscapine [mi]
101. Noscapine [hsdb]
102. Prestwick0_000563
103. Prestwick1_000563
104. Prestwick2_000563
105. Prestwick3_000563
106. Narcotinum [hpus]
107. Cbmicro_048259
108. Noscapine [mart.]
109. Noscapine [usp-rs]
110. Noscapine [who-dd]
111. Noscapine [who-ip]
112. Schembl4559
113. (s,r)-noscapine, 97%
114. Lopac0_000840
115. Bspbio_000346
116. 4-27-00-06838 (beilstein Handbook Reference)
117. Mls000069475
118. Mls001060855
119. Spbio_002565
120. Noscapine (jp15/usp/inn)
121. Noscapine (jp17/usp/inn)
122. Bpbio1_000382
123. Chembl364713
124. Noscapine Dl-form [mi]
125. Dtxsid4023385
126. Noscapine [ep Monograph]
127. Noscapine, (+/-)-
128. Gtpl10212
129. Noscapine [usp Monograph]
130. Noscapinum [who-ip Latin]
131. Dtxsid901032089
132. Hms1569b08
133. Hms2096b08
134. Hms2269p05
135. 1(3h)-isobenzofuranone, 6,7-dimethoxy-3-((5r)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (3s)-
136. 6,7-dimethoxy-3-(4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-2-benzofuran-1(3h)-one, (s-(r*,s*))- #
137. Phthalide, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-
138. (+/-)-.alpha.-narcotine
139. Tox21_110413
140. Bbl012344
141. Bdbm50424716
142. Mfcd00069316
143. Nsc121869
144. Stk054401
145. Zinc19418974
146. Noscapine 1.0 Mg/ml In Acetonitrile
147. Akos000278036
148. Tox21_110413_1
149. Ccg-204096
150. Cs-5115
151. Db06174
152. Nsc-121869
153. Sdccgsbi-0048054.p004
154. (-)-3-(2-methyl-6,7-methylendioxy-8-methoxy-1-isochinolyl)-6,7-dimethoxyphthalid
155. Ncgc00023230-02
156. Ncgc00023230-04
157. Ncgc00023230-05
158. Ncgc00023230-07
159. Ncgc00023230-08
160. Ncgc00023230-10
161. Ncgc00023230-14
162. (3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-5,6,7,8-tetrahydro-2h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-2-benzofuran-1(3h)-one
163. (3s)-6,7-dimethoxy-3-[(5r)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-1(3h)-isobenzofuranone
164. 5-(6,7-dimethoxyphthalidyl)-5,6,7,8-tetrahydro-4-methoxy-8-methyl-1,3-dioxolo(4,5-g)isoquinoline
165. Ac-20272
166. Ac-33191
167. Hy-13716
168. L-alpha-2-methyl-8-methoxy-6,7-methylenedioxy-1-(6,7-dimethoxy-3-phthalidyl)-1,2,3,4-tetrahydroisoquinaline
169. Nci60_004322
170. Vs-03291
171. Bim-0048054.p001
172. C09592
173. D01036
174. Sr-01000075529-6
175. W-201012
176. Brd-k89237706-001-03-8
177. Q60998699
178. Noscapine, European Pharmacopoeia (ep) Reference Standard
179. Noscapine, United States Pharmacopeia (usp) Reference Standard
180. Wln: T C566 Do Fo Kn Eh & & Tj Ho1 K1 J-dt56 Bvo Dhj Ho1 Io1
181. (3s)-3-[(5r)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3h)-one
182. (3s)-6,7-dimethoxy-3-[(5r)-4-methoxy-6-methyl-7,8-dihydro-5h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-3h-isobenzofuran-1-one
183. 08n
184. 1(3h)-isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo(4,5-g)isoquinolin-5-yl)-, (r*,s*)-(+-)-
185. 1(3h)-isobenzofuranone,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-, [s-(r*,s*)]-
186. Phthalide,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl)-
| Molecular Weight | 413.4 g/mol |
|---|---|
| Molecular Formula | C22H23NO7 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 413.14745207 g/mol |
| Monoisotopic Mass | 413.14745207 g/mol |
| Topological Polar Surface Area | 75.7 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 647 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Antitussive Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
ANTITUSSIVE AGENT WHICH DEPRESSES MEDULLARY CENTERS & SUPPRESSES COUGH REFLEX. IT IS USED IN MGMNT OF COUGH IN BRONCHIAL ASTHMA & PULMONARY EMPHYSEMA. DRUG REDUCES FREQUENCY & INTENSITY OF COUGHING PAROXYSMS.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 805
DRUG HAS NO MORPHINE-LIKE EFFECTS & HAS NO EFFECT ON MORPHNE ABSTINENCE SYNDROME. TOLERANCE TO ANTITUSSIVE EFFECT HAS NOT BEEN OBSERVED. NOSCAPINE IS NO LONGER CONTROLLED UNDER FEDERAL NARCOTIC LAW.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 805
NOSCAPINE HAS NO ANALGESIC PROPERTIES OR DEPENDENCE LIABILITY.
American Medical Association, AMA Department of Drugs, AMA Drug Evaluations. 3rd ed. Littleton, Massachusetts: PSG Publishing Co., Inc., 1977., p. 667
NOSCAPINE HAD NO ANTITUSSIVE ACTIVITY IN VOLUNTEERS.
EMPEY ET AL; COMPARISON OF THE ANTITUSSIVE EFFECTS OF CODEINE PHOSPHATE 20 MG, DEXTROMETHORPHAN 30 MG AND NOSCAPINE 30 MG USING CITRIC ACID-INDUCED COUGH IN NORMAL SUBJECTS; EUR J CLIN PHARMACOL 16(6) 393 (1979)
THERAPEUTICALLY EFFECTIVE DOSES ARE ESSENTIALLY DEVOID OF UNPLEASANT SIDE EFFECTS OF CODEINE &, EXCEPT FOR OCCASIONAL NAUSEA, ITS SIDE EFFECTS ARE NEGLIGIBLE. DOSES UP TO 90 MG HAVE NO EFFECT ON RESPIRATION IN MAN.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 805
SIDE EFFECTS, PREDOMINANTLY GI, ARE SEEN IN UP TO 30% OF PT STUDIED.
Miller, R. R., and D. J. Greenblatt. Handbook of Drug Therapy. New York: Elsevier North Holland, 1979., p. 988
Maternal Medication usually Compatible with Breast-Feeding: Noscapine: Reported Sign or Symptom in Infant or Effect on Lactation: None. /from Table 6/
Report of the American Academy of Pediatrics Committee on Drugs in Pediatrics 93 (1): 141 (1994)
Investigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), cancer/tumors (unspecified), and multiple myeloma.
Antitussive Agents
Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally. (See all compounds classified as Antitussive Agents.)
R - Respiratory system
R05 - Cough and cold preparations
R05D - Cough suppressants, excl. combinations with expectorants
R05DA - Opium alkaloids and derivatives
R05DA07 - Noscapine
ITS ANTITUSSIVE POTENCY & ONSET & DURATION OF ACTION ARE APPROX EQUAL, MG FOR MG, TO THOSE OF CODEINE.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 805
MECONIN WAS THE MAJOR URINARY METABOLITE OF RATS, RABBITS, & HUMANS WHO HAD RECEIVED 120, 150 MG/KG & 10 MG, RESPECTIVELY, ORALLY. IT ACCOUNTED FOR APPROX 3, 8, & 2% OF DOSE RESPECTIVELY, AFTER 24 HR. O-DEMETHYLATED METABOLITES WERE ALSO FOUND.
TSUNODA, YOSHIMURA; XENOBIOTICA 9(3) 181 (1979)
Noscapine's antitussive effects appear to be primarily mediated by its sigma receptor agonist activity. Evidence for this mechanism is suggested by experimental evidence in rats. Pretreatment with rimcazole, a sigma specific antagonist, causes a dose-dependent reduction in antitussive activity of noscapine.
...EXCEPT FOR ITS ANTITUSSIVE EFFECT, IT HAS NO SIGNIFICANT ACTIONS ON CNS IN DOSES WITHIN THERAPEUTIC RANGE.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 279
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
75
PharmaCompass offers a list of Noscapine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Noscapine manufacturer or Noscapine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Noscapine manufacturer or Noscapine supplier.
PharmaCompass also assists you with knowing the Noscapine API Price utilized in the formulation of products. Noscapine API Price is not always fixed or binding as the Noscapine Price is obtained through a variety of data sources. The Noscapine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Noscapina manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Noscapina, including repackagers and relabelers. The FDA regulates Noscapina manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Noscapina API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Noscapina manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Noscapina supplier is an individual or a company that provides Noscapina active pharmaceutical ingredient (API) or Noscapina finished formulations upon request. The Noscapina suppliers may include Noscapina API manufacturers, exporters, distributors and traders.
click here to find a list of Noscapina suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Noscapina DMF (Drug Master File) is a document detailing the whole manufacturing process of Noscapina active pharmaceutical ingredient (API) in detail. Different forms of Noscapina DMFs exist exist since differing nations have different regulations, such as Noscapina USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Noscapina DMF submitted to regulatory agencies in the US is known as a USDMF. Noscapina USDMF includes data on Noscapina's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Noscapina USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Noscapina suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Noscapina Drug Master File in Japan (Noscapina JDMF) empowers Noscapina API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Noscapina JDMF during the approval evaluation for pharmaceutical products. At the time of Noscapina JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Noscapina suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Noscapina Drug Master File in Korea (Noscapina KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Noscapina. The MFDS reviews the Noscapina KDMF as part of the drug registration process and uses the information provided in the Noscapina KDMF to evaluate the safety and efficacy of the drug.
After submitting a Noscapina KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Noscapina API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Noscapina suppliers with KDMF on PharmaCompass.
A Noscapina CEP of the European Pharmacopoeia monograph is often referred to as a Noscapina Certificate of Suitability (COS). The purpose of a Noscapina CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Noscapina EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Noscapina to their clients by showing that a Noscapina CEP has been issued for it. The manufacturer submits a Noscapina CEP (COS) as part of the market authorization procedure, and it takes on the role of a Noscapina CEP holder for the record. Additionally, the data presented in the Noscapina CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Noscapina DMF.
A Noscapina CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Noscapina CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Noscapina suppliers with CEP (COS) on PharmaCompass.
A Noscapina written confirmation (Noscapina WC) is an official document issued by a regulatory agency to a Noscapina manufacturer, verifying that the manufacturing facility of a Noscapina active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Noscapina APIs or Noscapina finished pharmaceutical products to another nation, regulatory agencies frequently require a Noscapina WC (written confirmation) as part of the regulatory process.
click here to find a list of Noscapina suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Noscapina as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Noscapina API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Noscapina as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Noscapina and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Noscapina NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Noscapina suppliers with NDC on PharmaCompass.
Noscapina Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Noscapina GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Noscapina GMP manufacturer or Noscapina GMP API supplier for your needs.
A Noscapina CoA (Certificate of Analysis) is a formal document that attests to Noscapina's compliance with Noscapina specifications and serves as a tool for batch-level quality control.
Noscapina CoA mostly includes findings from lab analyses of a specific batch. For each Noscapina CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Noscapina may be tested according to a variety of international standards, such as European Pharmacopoeia (Noscapina EP), Noscapina JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Noscapina USP).
